Stockreport

Why Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet Syndrome [Yahoo! Finance]

Stoke Therapeutics, Inc.  (STOK) 
Last stoke therapeutics, inc. earnings: 11/12 08:00 am Check Earnings Report
PDF sustained improvements in cognition, behavior, and overall clinical status for patients with Dravet syndrome, presented at the 54th Child Neurology Society Annual Meetin [Read more]